

COVID-19 a global crisis: Features, complications and suggested treatments

Mustafa M. Abo-Elala¹, Nermeen A. ElKasabgy²

Correspondence:

Nermeen Adel ElKasabgy
Department of Pharmaceutics and
Industrial Pharmacy, Faculty of
Pharmacy, Cairo University, Cairo
11562, Egypt

E-mail:
nermeen.ahmed.elkasabgy@pharm.a.cu.edu.eg

¹ Hefny pharma group, Cairo,
Egypt, Cairo, Egypt.

² Department of Pharmaceutics
and Industrial Pharmacy, Faculty of
Pharmacy, Cairo University, Cairo
11562, Egypt

Volume number 1

Issue number 2

Pages 43-55

10.61466/ijcmr1020007

Received: 15.07.2023

Accepted: 22.08.2023

Published: 25.08.2023

Online: 01.10.2023

Abstract

Coronavirus disease 2019 (COVID-19); caused by the novel coronavirus (SARS-CoV-2) is the talk of everyone all over the world in 2020 since it has been considered as a public health emergency of international concern by WHO in 30th January, 2020. COVID-19 is a highly transmittable disease with different symptoms which can vary from mild to severe and life threatening. Scientists all over the world are working on finding a treatment or vaccine for this disease. All of these studies are currently not finished yet during writing this review. However, in this review a summary about the current status of these studies is given. This summary includes medicinal plants and natural products, antivirals like remdesivir, favipiravir, oseltamivir and nelfinavir as well as other miscellaneous drugs like chloroquine, hydroxychloroquine and ivermectin which showed promising results in treating COVID-19. In conclusion, the review recommends conducting further investigations worldwide and reporting them in peer-reviewed publications to aid in improving the drugs' dosing regimens and clinical studies.

Keywords: Covid-19; SARS-CoV-2; Pneumonia; Vaccination; Antivirals; Hydroxychloroquine

Introduction

Coronaviruses are large group of viruses which were not highly pathogenic to humans till the occurrence of the first outbreak of the severe acute respiratory syndrome (SARS) in November, 2002 in Guangdong, China ¹. In 2012, the second outbreak of the Middle East respiratory syndrome (MERS) emerged by another new coronavirus in Saudi Arabia ². Both epidemics highlighted the great threat which these types of viruses could make globally to the health security ³. Finally in December, 2019 in Wuhan, China the third coronavirus epidemic originated. As discovered at the end of 2019, it was called by World Health Organization (WHO) on 12th January, 2020 as COVID-19 ⁴. COVID-19 was declared a global pandemic by the WHO on 11th March, 2020 ⁵. The International Committee on Taxonomy of Viruses (ICTV) named the causing virus of COVID-19 as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ⁶.

Coronaviruses are characterized by the presence of crown-like spikes on their surfaces. Many coronaviruses can circulate and transmit between animals however some of them can infect humans (7 types). Occurrence of SARS, MERS and COVID-19 might be associated with civet cats, camels and bats, respectively ⁷. Unfortunately, 213 countries around the world have recorded 5,103,350 infected cases and a total of 329,925 deaths from COVID-19 ⁸. This confirmed the severity of the disease compared to SARS (from 1 November 2002 to 31 July 2003) and MERS (since 2012) where the number of deaths were 774 ⁹ and 858, in that order ¹⁰.

A comparison between the three diseases caused by coronaviruses is collected in Table 1.

The number of scientific papers recorded in PubMed in 2020 using a search term "Treatment of COVID-19" was 1696. Additionally, searching using "COVID-19 articles" and "COVID-19 reviews" resulted in 3840 and 704 records, in that order. These statistical results in one year represent the very great importance of the topic and the need for further investigations to combat the virus and win the battle. Hence, the authors are presenting this review to highlight on the possible ways of prevention and treatment of COVID-19 as well as offering new suggestions to pass the crisis.

Table 1: Brief comparison between SARS, MERS, and COVID-19 diseases

| Comparison points | SARS | MERS | COVID-19 |
|-----------------------------|--|---------------------|--------------------------------------|
| Causing virus | SARS-CoV | MERS-CoV | SARS-CoV-2 |
| Year of the outbreak | 2002 | 2012 | 2019 |
| Country of origin | China | Saudi Arabia | China |
| Disease spread | Epidemic | Epidemic | Pandemic |
| Key hosts | Civet cats | Camels | Bats |
| Number of deaths | 774 (1 November 2002 to 31 July 2003) | 885 (since 2012) | 329,925 (On 21 st May) |
| Year of containment | 2003 | Not identified | Not yet |

Methods of transmission

Unfortunately, all the countries all over the world weren't prepared for such highly infectious and transmitting disease, creating an exceptional stress on all healthcare systems. The transmission rate of SARS-CoV-2 is higher than any other corona viruses which might be due to the genetic mutations ¹¹. Person to person transmittance is the major method of infection. Additionally, transmission through fomites has been reported ¹². This way of transmittance is called cross-contamination which may occur from contaminated surfaces—by other people or even yourself- which can be a possible way of transmitting the disease if the person touched these surfaces then put his hands on eyes, nose or mouth. Although, using a mask or gloves can keep us safe however touching them with dirty hands can be a source of infection ¹³. So, the best advice to protect ourselves from infection is hand-washing using soap and water ¹³. Additionally, proactive detection for the confirmed cases is of great importance for isolation measures.

Regarding the air-borne transmittance, it is still controversial. A study conducted by Su et al, negated the possibility of air-borne transmittance of the virus after analyzing air samples in the environment of symptomatic COVID-19 patients ^{12, 14}. However, the WHO didn't give a final decision about this issue till more studies are conducted and published.

Transmission and spread can also occur through conjunctiva ¹⁵. Special attention should be given also to closed areas where non-fresh air can lead to increased virus density causing facile spread. Hence, developing an effective anti-viral drug to eradicate or even reduce the viral load is required promptly to limit the progression of the disease and to stop its transmission.

Symptoms

Disease symptoms may happen within 2 to 14 days after being exposed to the virus. SARS-CoV-2 can infect any age range, however geriatrics, adults with chronic diseases like diabetes, heart or lung diseases and pregnant women are more vulnerable to more severe complications from COVID-19 ^{16, 17}. Several studies stated that men are more affected by SARS-CoV-2 than women ^{18, 19}, however this gender difference might be due to different exposure due to work needs reporting and susceptibility.

COVID-19 occurs more frequently among adults more than or equal to 15 years old, with little proportion of infections among children. Unfortunately, this hypothesis didn't offer special preventive measures for children -like wearing masks- which resulted in increasing the number of infected children ²⁰. Consequently, the PCR stated that children are vulnerable to COVID-19 disease due to their immature immune system ²¹. Hence, more attention should be given to these age range (among infants and children) especially that they are not mature enough to protect themselves or even describe their medical situation as well as they more susceptible to cross contamination from their families. Literature includes several examples for symptomatic and asymptomatic children with COVID-19 ²¹⁻²³.

Symptoms range from mild to severe. Mild symptoms are like having cough, sore throat, fever, chills, muscle pain, headache and short breath, while severe ones include chest pain, persistent high fever, pneumonia and difficulty to breath requiring prompt hospitalization and mechanical ventilation ¹⁷. A comparison between common cold and COVID-19 symptoms is collected briefly ²⁴ in Table 2.


Economic impact of COVID-19

The continuously and rapidly increasing numbers of confirmed cases and deaths are posing extreme challenges on all the countries, which require a worldwide solidarity strategy ²⁵. The worldwide map of the spread of COVID-19 is presented in Figure 1 ²⁶. Almost all the affected countries are imposing strict precautionary measures like lockdown and airlines lock which in turn has negative economic impacts causing challenging economic crises. Although the problem is worldwide however its economic effect is deeply local. Investment in public health would assist in the rapid recovery from COVID-19 pandemic. The World Bank Group launched emergency health support to help developing countries to combat COVID-19 providing \$160 billion over the next 15 months ²⁷.

Table 2: A brief comparison between common cold and COVID-19 symptoms

| Symptoms \ Disease | Common cold | COVID-19 |
|--|-------------|----------------------------------|
| Cough | Sometimes | Persistent and dry |
| Fever | Sometimes | Present and can be of high grade |
| Runny nose | Present | Sometimes |
| Sneezing | Present | Sometimes |
| Fatigue | Present | Ranges from mild to severe |
| Conjunctivitis | Sometimes | Present and can be very severe |
| Relief by anti-histaminics | Yes | No |
| Difficulty in breathing | No | Yes and sometimes is very severe |
| Need for mechanical ventilation | No | Sometimes |

Hence, this review introduces the different trials conducted for developing a safe and effective vaccine as well as an efficient medication. An illustrative figure combining the symptoms and different effects of COVID-19 as well as the required measures are presented in Figure 2.

**Fig. 1: Global map of confirmed cases of COVID-19 (accessed on 21st May 2020)**

Vaccination

No vaccine is available up till now for COVID-19 disease, however there are several attempts for developing such vaccine. The WHO started an initiative called “WHO Solidarity Trial” for hastening the development of an effective vaccine against COVID-19²⁸. WHO stated in February, 2020 that it is not expected to get a vaccine against SARS-CoV-2 before 18 months. On the other hand, the Coalition for Epidemic Preparedness Innovations (CEPI) indicated in April, 2020 that a vaccine may be available under emergency use by early 2021. On 8th April, 2020, 115 vaccine candidates were in development, with five organizations having initiated phase 1 safety studies in human subjects²⁹. CEPI increased the funding for phase 1 and 2 clinical trials on Novavax ‘NVX-CoV2373’ vaccine as well as supporting its large scale production. Phase 1 results are expected to be ready in July, 2020³⁰. On 5th May, CEPI has launched a call for funding to accelerate the global COVID-19 vaccine development guided by three imperatives: speed of manufacture, safety and global accessibility³¹.

On 16th March, 2020, Jennifer Haller a 43 old American citizen and three more participants were the first to be enrolled in phase 1 clinical trials at the Kaiser Permanente Washington Health Research Institute in Seattle on mRNA-1273 vaccine developed by the National Institutes of Health and is made from synthetic virus particles depending on digital information instead of using physical virus. All participants will be monitored for 14 months to

decide the efficacy of the vaccine, however up till now no side effects were recorded ³².

International cooperation between all vaccine developers, funders, health sectors and countries is required to support the prompt production of an effective vaccine in sufficient amounts and to ensure supplying all countries especially low-resources ones.




Fig. 2: An illustrative diagram representing the transmission, symptoms, different effects of COVID-19 as well as the required measures.

Prevention and treatments

Medicinal Plants and natural products

Several medicinal plants and their extracted compounds have been reported to have antiviral activities against several viral infections such as those caused by coronavirus ³³⁻³⁶. Cinatl et al. assessed the antiviral activity of several medicinal compounds in Vero cells against 2 clinical coronavirus isolates (FFM-1 and FFM-2) from SARS infected patients. Of all the tested compounds, glycyrrhizin extracted from liquorice roots showed to be the most active in preventing the replication of the SARS virus. They suggested that glycyrrhizin should be evaluated for treating SARS ³⁷. Another study conducted by Wen and coworkers stated that 221 phytochemicals were evaluated for their activity against SARS-CoV. They used a cell-based assay measuring SARS-CoV-induced cytopathogenic effects on Vero E6 cells. They observed that about 20 out of the 221 phytochemicals especially; piceic abietane-type diterpenoids and lignoids were potent inhibitors for SARS-CoV ³⁸. Moreover, Khaerunnisa et al., assessed some bioactive compounds found in several medicinal plants as potential COVID-19 main protease inhibitors, using a molecular docking study. They found that kaempferol, quercetin, luteolin-7-glucoside, demethoxycurcumin, naringenin, apigenin-7-glucoside, oleuropein, curcumin, catechin, and epicatechin-gallate might act as COVID-19 main protease inhibitors; however further investigations are required to approve their medicinal benefits ³⁹.

Vitamin D is a fat soluble pro-hormone that supports the immune system ⁴⁰. Unfortunately, not much food is rich in vitamin D. Vitamin D3 is formed in skin after exposure to ultraviolet B rays from sunlight which is further activated by liver and kidney ⁴¹. However, this process decreases by aging and during winter season; subjecting elderly people and citizens of cold countries especially at latitudes more than 40° to vitamin D deficiency problems ⁴². This seasonal deficiency has been associated with respiratory infections like the spread of influenza virus in winter ⁴³⁻⁴⁵. Vitamin D is essential for regulating and suppressing the inflammatory cytokine response hence avoiding the incidence of acute respiratory distress syndrome ⁴⁶⁻⁴⁸. The failure of this inflammatory cytokine response suppression was indicated to be responsible for the severe complications of COVID-19 ⁴⁹. Additionally, the geographical correlation between vitamin D deficiency and the elevated infection and mortality rates due to COVID-19 could support the beneficial effect of vitamin D on COVID-19 patients. It was previously stated by Daneshkhah et al that the rate of fatality from COVID-19 was very high in Italy, Spain, France and European countries with high incidence of vitamin D deficiency ⁵⁰. Additionally, Rhodes et al. showed that the mortality rate from COVID-19 was

moderately low for territories below 35° latitude ⁵¹. Hence, supplementation with vitamin D might help in reducing the mortality rates from the pandemic. This suggestion was published before by Marik et al ⁵².

Based on these preliminary promising results, this review highlights the need to exploit the medicinal plants as well as natural products in treating COVID-19 infected patients to benefit from their low costs and availability, more and above being natural is highly appreciated.

Antiviral drugs

Several antiviral drugs are currently under investigation for their efficacy against COVID-19. They exert their activity by different actions such as protease inhibition, neuraminidase inhibition and as being nucleoside analogs ⁵³. These antiviral drugs are used in clinical trials either alone or with multiple combinations with other drugs such as interferon, hydroxychloroquine and azithromycin ⁵⁴. This review focuses here on the most promising candidates in treatment of COVID-19.

Remdesivir

Remdesivir (formerly known as GS-5734) is a nucleotide analogue inhibitor of viral RNA-dependent RNA-polymerase ⁵⁵. It is the most promising direct-acting antiviral currently being investigated for COVID-19. It is not currently approved for any indication. In 2nd April 2020, its compassionate use was accepted by the European medicines agency Committee for Medicinal Products for Human Use (CHMP) ⁵⁶. In 1st May 2020, U.S. Food and drug administration has approved emergency use authorization for remdesivir in treating hospitalized COVID-19 patients ⁵⁷. This will increase and facilitate its use in different hospitals but with strict regulations and in severe cases. Remdesivir for compassionate use is provided in two dosage forms, “concentrate for solution for infusion” and “powder for concentrate for solution for infusion” ⁵⁶.

Remdesivir is a prodrug which is converted after intravenous administration into an intermediate metabolite (GS-704277) as well as a nucleoside one (GS-441524). Then inside the cells, the GS-441524 monophosphate is converted rapidly into the pharmacologically active analog of adenosine triphosphate (GS-443902) which inhibits viral RNA polymerases. It is not suitable for oral administration as it will be subjected to extensive first pass metabolism ⁵⁸. As being still under investigation, its safety profile is incompletely characterized. The solitary side effect that seems clearly linked to the use of remdesivir is increasing the transaminases. But generally regarding its use in COVID-19, the safety profile is compatible with compassionate use in the proposed target population ⁵⁶. There are several clinical trials which began in US, China and other countries to test the efficacy of remdesivir in COVID-19 patients. In the study performed in China by Wang et al on adult hospitalized patients for severe COVID-19, patients were randomized in a ratio of 2:1 to take remdesivir (200 mg IV on day 1, then 100 mg IV once daily from 2nd to 10th day) or placebo; started within 12 days of symptoms onset. Intention to treat (ITT) population included 158 patients treated with remdesivir and 78 patients treated with placebo; some of the treated patients received interferon α -2b or lopinavir–ritonavir or corticosteroids during hospitalization. They concluded that remdesivir didn't show any statistically significant clinical benefits. Nevertheless, the obtained numerical reduction in time till clinical progress in patients treated before needs to be confirmed in larger studies. Registration was ended before the pre-specified number of patients was reached as the outbreak of COVID-19 was controlled in China ⁵⁹. In a different study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) with ClinicalTrials.gov, patients received remdesivir (200 mg IV on day 1, then 100 mg once daily during the hospitalization period of up to 10 days total) or placebo ⁶⁰. Preliminary data analysis indicated smaller median time to recover in remdesivir group (11 days) *versus* placebo group (15 days) and recommended that remdesivir treatment might have delivered a survival benefit (mortality rate 8% in remdesivir group *versus* 11.6% in placebo group ⁶¹). The remdesivir manufacturer (Gilead company) is studying extensively the safety as well as the antiviral activity of remdesivir in contributors with severe COVID-19 complications ⁶⁰. Gilead conducted a study to investigate if a shorter period (5 days) of treatment would give the same clinical efficacy as longer period of 10 days. Gilead proclaimed that the available information for the first 397 participants with pneumonia and reduced levels of oxygen but not requiring mechanical ventilation indicated comparable clinical enhancement with both treatment durations. The duration to clinical improvement in half the participants in the 5-day treatment group was 10 days *versus* 11 days in the 10-day treatment group. Clinical recovery after 14 days was achieved in 64.5% and 53.8% of the patients in the short and long duration treatment groups, correspondingly. Generally, it was concluded that early treatment would assist in improving clinical outcomes as participants who were treated within 10 days of symptom onset possessed enhanced clinical outcomes in comparison to other patients who took medication after 10 days of symptoms ⁶². Another study carried out by Gilead is appraising the safety and antiviral activity of remdesivir after 5 and 10 days of treatment but in conjunction with standard of care in comparison to the standard of care alone ⁶⁰. The results from the first 600 patients of this study are expected at the end of May ⁶².

Favipiravir

Favipiravir is another antiviral drug under investigation for treatment of COVID-19. It was approved for treatment of influenza in 2014 in Japan. But this approval was limited to certain cases; just when the government judges that the drug can be used as a countermeasure against new or re-emerging influenza viruses ⁶³. Moreover, favipiravir has been used for further indications for severe fever with thrombocytopenia syndrome depending on clinical trials besides influenza in Japan ⁶⁴. Favipiravir is available as film coated tablets under the trade name of Avigan tablets. Favipiravir is a prodrug which is metabolized into the active form; favipiravir ribosyl triphosphate by an intracellular

enzyme. This active form selectively inhibits viral RNA-dependent RNA polymerase, preventing replication of the virus ⁶⁵. Favipiravir is rapidly absorbed after oral administration with high bioavailability near to 100%. It is mainly eliminated through hepatic metabolism by aldehyde oxidase, and marginally xanthine oxidase, giving inactive metabolite, which is removed in the urine ⁶⁶. Adverse effects of favipiravir are still not accurately stated, as Avigan hasn't been administered with the approved dosage before the COVID-19 pandemic. In Japanese clinical studies and the global phase 3 study performed on lower therapeutic doses, chief opposing reactions comprised rise in blood uric acid level in 24 participants (4.79%), diarrhea in 24 participants (4.79%), decrease of neutrophil count in 9 participants (1.80%), increase of AST enzymes in 9 participants (1.80%), increase of ALT enzymes in 8 participants (1.60%) ⁶³.

Safety and efficacy of the drug is now under investigation in multiple clinical trials in patients with COVID-19 in China, Japan and other countries. Wang et al carried out an open-label multicenter trial on adult infected patients with COVID-19. Patients were randomly classified in a 1:1 ratio to get the conventional therapy in addition to favipiravir (1600 mg orally twice daily on day 1, then 600 mg orally twice daily thereafter for 10 days) or umifenovir (200 mg 3 times daily for 10 days). Both groups were judged according the clinical recovery rate on the seventh day where results clarified that no significant difference was detected between both groups. On the other hand, favipiravir significantly shortened the latency for pyrexia and cough relief. Moreover, they concluded that antiviral-related opposing effects of favipiravir are mild and controllable ⁶⁷.

In another small, open-label, non-randomized study in COVID-19 patients in China conducted by Liu et al, favipiravir (n=35) was compared *versus* lopinavir/ritonavir (n=45). Favipiravir was administered in a dose regimen as follows: 1600 mg orally twice daily on the first day followed by 600 mg orally twice daily on days 2 to 14 while lopinavir/ritonavir were administered twice daily (400 mg/100 mg) from days 1 to 14. In addition, the two groups received aerosolized interferon α -1b. In comparison to lopinavir/ritonavir group, it was observed that favipiravir group was accompanied with reduced median time to viral clearance (4 *versus* 11 days) and advanced improvement rate on chest CT imaging on day 14 (91 *versus* 62%). Based on their findings, they concluded that favipiravir showed significantly better treatment effects on COVID-19 in terms of disease progression and viral clearance ⁶⁸. This study could provide significant information for establishing standard treatment guidelines for treating COVID-19.

Oseltamivir

Oseltamivir is a viral neuraminidase inhibitor. It is approved by FDA under trade name, Tamiflu for treating influenza virus ⁵⁵. Oseltamivir is available in two dosage forms; capsules and powder for oral suspension ⁶⁹.

Oseltamivir is marketed in the form of phosphate salt which is a prodrug. After oral administration, it is rapidly converted by hepatic esterases into the active carboxylate form which has an absolute bioavailability of about 80%. It is systemically distributed reaching the lung in therapeutic concentrations ⁷⁰. Oseltamivir has a broad safety margin in acute, subacute and chronic toxicity studies ⁷¹. Moreover, it is well tolerated with mild side effects like nausea and vomiting. On the other hand, rare serious skin hypersensitivity reactions and neuropsychiatric events have been reported in post marketing experience ⁶⁹.

Oseltamivir use for COVID-19 has been reported in China with and without either corticosteroids or antibiotics. But there is no precise indication to date that oseltamivir is efficient in the treatment of COVID-19 ⁵⁴. In 9th May 2020, 17 clinical trials for COVID-19 that included the use of oseltamivir were available at Clinicaltrials.gov ⁶⁰. It is used in these clinical trials with multiple combinations with different drugs such as hydroxychloroquine, azithromycin, lopinavir/ritonavir, and favipiravir. None of these studies has been completed till this day.

Nelfinavir mesylate

Nelfinavir is an HIV-1 protease inhibitor ⁷². It has low and variable bioavailability ⁷³. The bioavailability of the drug differs according to the age where infants (1 year old) require higher doses in comparison to older children and adults which might be attributed to the extensive first pass metabolism or feeding protocols in infants ⁷⁴.

Nelfinavir has shown strong inhibition against SARS-CoV. Nelfinavir acted by inhibiting the cytopathic effect induced by the virus as well as reducing the production of virions from Vero cells. It was also observed that the expression of the viral antigens decreased in treated cells with nelfinavir in comparison to untreated ones. This study suggested the use of nelfinavir in extra clinical studies as an anti-SARS drug ⁷². Hence, nelfinavir could be a good lead for designing an effective treatment against COVID-19. Nelfinavir showed certain activity against SARS-CoV-2 replication ⁷⁵. Transient transfection of African green monkey kidney (Vero) cells with SARS-CoV-2 resulted in extensive cell fusion mainly due to expression of SARS CoV-2 S (S-n) glycoprotein and to some extent due to SARS S (S-o) glycoprotein. S-n glycoprotein is responsible for formation of large multinucleated cells 48 h after transfection. Nelfinavir (10 μ M) succeeded to inhibit S-n and S-o cell fusion mechanisms. Additionally, nelfinavir might inhibit S proteolytic processing ⁷⁶. These results open the door for extra applications of the drug for treating COVID-19 patients especially at early stages of the disease.

Some Japanese researchers stated that combining nelfinavir and cepharanthine (anti-inflammatory) showed effective clearing of SARS-CoV-2 virus in laboratory investigations. Nelfinavir inhibits the virus replication by binding it while cepharanthine halts the attachment and entering of the virus to the cells ⁷⁷.

Miscellaneous drugs

Chloroquine phosphate

Chloroquine phosphate is the effective synthetic substitute of natural quinine^{78,79}. For several decades, chloroquine was prescribed as the first choice for the prophylaxis and treatment of malaria⁸⁰. Chloroquine has high oral bioavailability approaching 78 and 89 % for solutions and tablets, in that order. Tissue bio-distribution indicated high accumulations of the drug in several tissues like liver and lungs. However, the drug has a narrow therapeutic range, which could result in drug poisoning effects; e.g, cardiovascular disorders⁸¹.

Besides its use as an antimalarial drug, chloroquine is also effective in treating some types of autoimmune diseases⁸². Additionally, this drug showed good antibacterial, antifungal as well as antiviral activity⁸³. This antiviral effect represented in its ability to inhibit the virus replication cycle was more explored after repositioning the drug in the treatment of human immunodeficiency virus in the middle of the 90s, although not highly effective⁸⁴. This repositioning and repurposing of the drug was mainly attributed to its low cost and tolerability⁸⁵. Evidences for some antiviral activity has been found in mice against some viruses like human coronavirus OC43⁸⁶, enterovirus EV-A71⁸⁷ and influenza A H5N1⁸⁸. However, it was not effective against influenza virus in ferrets⁸⁹ as well as in clinical trials⁹⁰. A promising effect against hepatitis C was observed in pilot study in non-responder patients, where a transient reduction in virus load was detected⁹¹.

With respect to coronaviruses, chloroquine showed notably the good therapeutic benefits against SARS-CoV-1^{85,86}. Additionally, it was reported by Keyaerts et al., that the growth of SARS coronavirus could be inhibited in cell cultures by chloroquine and hydroxychloroquine⁹².

It was detected that SARS-CoV-2 uses the cell surface receptor ACE2 found in several tissues as the case with SARSCoV-1⁹³. As chloroquine could successfully inhibit SARS-CoV-1 it can be postulated that the drug may act on ACE2 receptor glycosylation hence inhibiting the binding of SARS-CoV-2. SARS-CoV-2 favors the acidic pH inside the lysosome which facilitates the release of virus from the shell for replication and transfer to infect other cells⁹⁴. Chloroquine could interfere with the acidification trials of the virus to the lysosomes, hence preventing its replication⁹⁵.

All the previous data indicated that no successful treating for viral infections in human was reported. However, it was recently stated by Gao and his team that chloroquine improved the complications (e.g; pneumonia) of the viral infection in more than 100 patients; giving negative viral testing as well as shortening the infection period⁹⁶. Hence, these promising results presented the success of chloroquine in humans, however extra clinical trials on larger samples including, different age classes as well as different stages of the disease. Additionally, strict rules about monitoring the drug outcomes should be taken in the normal patient site; hospitals to avoid the risks of patient self-treatment at home.

Hydroxychloroquine sulfate

Hydroxychloroquine sulfate was synthesized from chloroquine by adding a hydroxyl group. Fortunately, it showed less toxicity by nearly 40% compared to the parent drug⁹⁷. Like the parent drug, hydroxychloroquine is used to treat malaria as well as autoimmune disorders like systemic lupus erythematosus and rheumatoid arthritis⁹⁸. Hydroxychloroquine possesses nearly the same pharmacokinetics as chloroquine⁹⁹. What makes hydroxychloroquine more favored than chloroquine is that it can be used in high doses for longer periods of time without causing any toxicities¹⁰⁰.

Hydroxychloroquine shares nearly the same mechanisms as chloroquine of being weak bases able to elevate the pH of the cell¹⁰¹ as well as altering the ACE2 receptor glycosylation¹⁰².

Clinical studies indicated that the plasma of COVID-19 infected patients contained high concentrations of cytokines¹⁴. As an anti-inflammatory, hence hydroxychloroquine can significantly reduce the production of cytokines so attenuating the associated inflammatory symptoms. Therefore, it can be concluded that hydroxychloroquine can act directly on the virus as well as combating its complications. Sharing nearly similar chemical structures, indications and mechanisms as well as referring to the achievements of chloroquine in dealing with SARS-CoV-2, so it is easy to evoke the idea of using hydroxychloroquine in treating SARS-CoV-2. Hydroxychloroquine was approved by the FDA in treating COVID-19 patients¹⁰³. However, more confirmation by clinical investigations is required. Several clinical trials were done to test the efficacy of hydroxychloroquine in treating COVID-19 patients. Hydroxychloroquine improved the patients' case and fastened the recovery when compared to the placebo¹⁰⁴. Additionally, it was observed that the drug succeeded in reducing the load of the virus or even its disappearance when co-administered with azithromycin¹⁰⁵.

In a clinical study performed on 62 patients infected with COVID-19, it was observed that patients treated with hydroxychloroquine showed shortened time for body temperature recovery as well as shortened cough remission time when compared to the control group. Additionally, the treated group was cured from pneumonia symptoms more than the control. On the other hand, 2 patients showed mild side reactions in hydroxychloroquine group¹⁰⁶.

Although the conducted clinical trials showed some promising results, however larger sample sizes are indicated.

Ivermectin

Ivermectin is a broad spectrum anti-parasitic drug approved by FDA for human use¹⁰⁷, it showed good *in-vitro* anti-viral activities against a wide range of viruses^{108,109}. Ivermectin was approved only orally in human with similar rate of absorption between solutions, suspensions and tablets¹⁰⁷. The absorption of the drug shows an enterohepatic

cycle¹¹⁰. However in some patients the oral route doesn't provide the required therapeutic levels¹¹¹, hence a shift to another route e.g; parental administration is required. The drug is widely distributed in the body due to its high lipid solubility¹⁰⁷. The drug is extensively metabolized by first pass effect by cytochrome P450¹¹². Ivermectin inhibited the interaction of the human immunodeficiency virus-1 integrase protein (IN) with the importin (IMP) α/β heterodimer which account for IN nuclear import¹¹³, hence inhibiting virus replication¹⁰⁹. This effect was endorsed to the IMP α/β nuclear import inhibitory characteristics of ivermectin¹⁰⁹. Additionally, ivermectin could limit the infection by RNA viruses¹¹⁴. Investigations on SARS-CoV proteins clarified the prospective role of (IMP) α/β during infection, which if inhibited could stop the division of the host cell¹¹⁵⁻¹¹⁷. Taken in consideration the role of ivermectin on inhibiting the IMP α/β nuclear import, hence it can be postulated that the drug may be effective against SARS-CoV-2. To approve the anti-SARS-CoV-2 activity of ivermectin, an *in-vitro* study on infected Vero/hSLAM cells was conducted which were treated with the addition of ivermectin. After 24 h, a significant reduction in the viral RNA could be observed in both the supernatant and the cell associated ones compared to the untreated cells¹¹⁸. This reduction increased after another 24 h and stopped on the 3rd day indicating the effective removal of all viral materials within 48 h without any cytotoxicity^{109, 114}. These promising open the door for further investigations on the drug as a potential treatment for COVID-19 patients.

Conclusions

COVID-19 presented a global crisis affecting the economic and health sectors in all affected countries. The disease symptoms range from mild to severe, however its transmission from person to person is considerably high. The number of confirmed cases besides the number of deaths is continuously increasing. Unfortunately, up till now no specific vaccination or treatment have been developed which represents a serious problem requiring a quick solution to stop this pandemic. The WHO started an initiative called "WHO Solidarity Trial" to accelerate the production of an efficient vaccine. This review highlights the several trials carried out for the development of an efficient vaccine and medication. Also, the review sheds the light on some medicinal plants of specific properties as well as vitamin D which might help in the battle against COVID-19. Several repurposed drugs were discussed in details for example, remdisvir, favipiravir, oseltamivir, nelfinavir, chloroquine, hydroxychloroquine and ivermectin highlighting their pharmacokinetics, mechanisms of actions as well as the *in-vitro* and *in-vivo* trials carried out to test their efficacy. In conclusion, this review suggests reporting all the trials running in all world countries in peer-reviewed publications to help the international scientific community to extract and analyze the data which could guide the formulators of improving the drugs' dosing regimens based on the pharmacokinetic information and setting protocols for future clinical studies.

Declaration of interests: We declare no competing interests.

References

1. WHO. SARS (Severe Acute Respiratory Syndrome). [cited 2020 18th May]; Available from: <https://www.who.int/ith/diseases/sars/en/>
2. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). [cited 2020 18th May]; Available from: <https://www.who.int/emergencies/mers-cov/en/>
3. Sifuentes-Rodríguez E, Palacios-Reyes D. COVID-19: The outbreak caused by a new coronavirus. Boletín Médico del Hospital Infantil de México. 2020; **77**(2): 47-53.
4. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infection, Genetics and Evolution. 2020; **79**: 104212.
5. WHO. WHO Timeline - COVID-19. [cited 2020 18th May]; Available from: <https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19>
6. ICTV. International Committee on Taxonomy of Viruses
ICTV. [cited 2020 19th May]; Available from: <https://talk.ictvonline.org/>
7. NLH. Coronaviruses. [cited 2020 18th May]; Available from: <https://www.niaid.nih.gov/diseases-conditions/coronaviruses>
8. Worldometer. Countries where COVID-19 has spread. [cited 2020 21st May]; Available from: <https://www.worldometers.info/coronavirus/countries-where-coronavirus-has-spread/>
9. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. [cited 2020 19th May]; Available from: https://www.who.int/csr/sars/country/table2004_04_21/en/
10. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). [cited 2020 19th May]; Available from: <https://www.who.int/emergencies/mers-cov/en/>
11. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of advanced research. 2020; **24**: 91-8.
12. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. Jama. 2020.
13. WBNG.COM. Cross-contamination: How a touch-and-go lifestyle can increase your risk for COVID-19. [cited 2020 3rd May]; Available from: <https://wbng.com/2020/04/08/cross-contamination-how-a-touch-and-go-lifestyle-can-increase-your-risk-for-covid-19/>

14. Cheng VC, Wong S-C, Chen JH, Yip CC, Chuang VW, Tsang OT, et al. Escalating infection control response to the rapidly evolving epidemiology of the Coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. *Infection Control & Hospital Epidemiology*. 2020: 1-6.
15. Jiatong S, Wenjun L. COVID-19 epidemic: disease characteristics in children. *Journal of Medical Virology*. 2020.
16. CDC. Pregnancy and Breastfeeding. [cited 2020 4th May]; Available from: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html>
17. CDC. Symptoms of Coronavirus. [cited 2020 4th May]; Available from: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>
18. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020; **395**(10223): 497-506.
19. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*. 2020; **395**(10223): 507-13.
20. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang Z-J. Novel coronavirus infection in hospitalized infants under 1 year of age in China. *Jama*. 2020; **323**(13): 1313-4.
21. She J, Liu W. Epidemiological characteristics and prevention and control measures of Corona Virus Disease 2019 in children. Luzhou, China: Department of Pediatrics, Southwest Medical University. 2020.
22. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet*. 2020; **395**(10223): 514-23.
23. Cai J, Wang X, Ge Y, Xia A, Chang H, Tian H, et al. First case of 2019 novel coronavirus infection in children in Shanghai. *Zhonghua er ke za zhi= Chinese journal of pediatrics*. 2020; **58**: E002.
24. ECDC. Q & A on COVID-19. [cited 2020 17th May]; Available from: <https://www.ecdc.europa.eu/en/covid-19/questions-answers>
25. UNDP. The Social and Economic Impact of Covid-19 in the Asia-Pacific Region. [cited 2020 4th May]; Available from: <https://www.undp.org/content/undp/en/home/librarypage/crisis-prevention-and-recovery/the-social-and-economic-impact-of-covid-19-in-asia-pacific.html>
26. CDC. World Map. [cited 2020 21st May]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/global-covid-19/world-map.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fworld-map.html
27. IBRD-IDA. The World Bank Group Moves Quickly to Help Countries Respond to COVID-19. [cited 2020 21st May]; Available from: <https://www.worldbank.org/en/news/feature/2020/04/02/the-world-bank-group-moves-quickly-to-help-countries-respond-to-covid-19>
28. WHO. Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine [cited 2020 4th May]; Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine>
29. Le TT, Andreadakis Z, Kumar A, Roman RG, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. *Nat Rev Drug Discov*. 2020; **19**: 305-6.
30. Biopharma. CEPI Extends Collaboration With Novavax To Advance Development and Manufacture of COVID-19 Vaccine. [cited 2020 17th May]; Available from: <https://www.technologynetworks.com/biopharma/product-news/cepi-extends-collaboration-with-novavax-to-advance-development-and-manufacture-of-covid-19-vaccine-334799>
31. CEPI. CEPI launches new funding opportunity to accelerate COVID-19 vaccine development and production. [cited 2020 17th May]; Available from: https://cepi.net/news_cepi/cepi-seeks-to-expand-covid-19-vaccine-portfolio-focusing-on-speed-and-global-manufacturing/
32. NPR. The Coronavirus Crisis. [cited 2020 17th May]; Available from: <https://www.npr.org/2020/03/21/818759617/i-wanted-to-do-something-says-mother-of-2-who-is-first-to-test-coronavirus-vacci>
33. Naithani R, Mehta RG, Shukla D, Chandrasekera SN, Moriarty RM. Antiviral activity of phytochemicals: a current perspective. *Dietary Components and Immune Function*: Springer; 2010. p. 421-68.
34. Cecílio AB, de Faria DB, de Carvalho Oliveira P, Caldas S, de Oliveira DA, Sobral MEG, et al. Screening of Brazilian medicinal plants for antiviral activity against rotavirus. *Journal of ethnopharmacology*. 2012; **141**(3): 975-81.
35. Chiow K, Phoon M, Putti T, Tan BK, Chow VT. Evaluation of antiviral activities of *Houttuynia cordata* Thunb. extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection. *Asian Pacific journal of tropical medicine*. 2016; **9**(1): 1-7.
36. Im K, Kim J, Min H. Ginseng, the natural effectual antiviral: protective effects of Korean Red Ginseng against viral infection. *Journal of ginseng research*. 2016; **40**(4): 309-14.
37. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. *The Lancet*. 2003; **361**(9374): 2045-6.

38. Wen C-C, Kuo Y-H, Jan J-T, Liang P-H, Wang S-Y, Liu H-G, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. *Journal of medicinal chemistry*. 2007; **50**(17): 4087-95.
39. Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study. Prepr doi10.20944/preprints202003.0226.v1. 2020: 1-14.
40. Rezaei R, Aslani S, Marashi M, Rezaei F, Sharif-Paghaleh E. Immunomodulatory Effects of Vitamin D in Influenza Infection. *Current Immunology Reviews*. 2018; **14**(1): 40-9.
41. Bikle D. Vitamin D: production, metabolism, and mechanisms of action. Endotext [Internet]: MDText. com, Inc.; 2017.
42. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. *The Journal of clinical investigation*. 1985; **76**(4): 1536-8.
43. Berry DJ, Hesketh K, Power C, Hyppönen E. Vitamin D status has a linear association with seasonal infections and lung function in British adults. *British Journal of Nutrition*. 2011; **106**(9): 1433-40.
44. Cannell J, Vieth R, Umhau J, Holick M, Grant W, Madronich S, et al. Epidemic influenza and vitamin D. *Epidemiology & Infection*. 2006; **134**(6): 1129-40.
45. Ginde AA, Mansbach JM, Camargo CA. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Archives of internal medicine*. 2009; **169**(4): 384-90.
46. Dancer RC, Parekh D, Lax S, D'Souza V, Zheng S, Bassford CR, et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). *Thorax*. 2015; **70**(7): 617-24.
47. Khare D, Godbole NM, Pawar SD, Mohan V, Pandey G, Gupta S, et al. Calcitriol [1, 25 [OH] 2 D3] pre-and post-treatment suppresses inflammatory response to influenza A (H1N1) infection in human lung A549 epithelial cells. *European journal of nutrition*. 2013; **52**(4): 1405-15.
48. Parlak E, Ertürk A, Çağ Y, Sebin E, Gümüşdere M. The effect of inflammatory cytokines and the level of vitamin D on prognosis in Crimean-Congo hemorrhagic fever. *International journal of clinical and experimental medicine*. 2015; **8**(10): 18302.
49. SciTechDaily. This may be because vitamin D is important in regulation and suppression of the inflammatory cytokine response, which causes the severe consequences of COVID-19 and 'acute respiratory distress syndrome' associated with ventilation and death. [cited 2020 16th May]; Available from: <https://scitechdaily.com/vitamin-d-determines-severity-in-covid-19-researchers-urge-government-to-change-advice/>
50. Daneshkhan A, Eshein A, Subramanian H, Roy HK, Backman V. The Role of Vitamin D in Suppressing Cytokine Storm in COVID-19 Patients and Associated Mortality. *MedRxiv*. 2020.
51. Rhodes JM, Subramanian S, Laird E, Anne Kenny R. low population mortality from COVID-19 in countries south of latitude 35 degrees North—supports vitamin D as a factor determining severity. *Alimentary pharmacology & therapeutics*. 2020.
52. Marik PE, Kory P, Varon J. Does vitamin D status impact mortality from SARS-CoV-2 infection? *Medicine in Drug Discovery*. 2020.
53. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. *Military Medical Research*. 2020; **7**(1): 1-10.
54. Pharmacists ASoH-S. Assessment of Evidence for COVID-19-Related Treatments: Updated 5/8/2020. [cited 2020 09 May]; Available from: <https://www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/Coronavirus/docs/ASHP-COVID-19-Evidence-Table.ashx?loc=ashphero2-evidencetable-05072020>
55. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. *Revista Panamericana de Salud Pública*. 2020; **44**: e40.
56. Agency EM. Summary on compassionate use. [cited 2020 09 May]; Available from: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
57. FDA. Emergency Use Authorization (EUA) for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. [cited 2020 9th May]; Available from: <https://www.fda.gov/media/137564/download>
58. Cao Y-c, Deng Q-x, Dai S-xJTM, Disease I. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. 2020: 101647.
59. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet*. 2020.
60. Medicine. USNLo. ClinicalTrials.gov. . [cited 2020 09 May]; Available from: <https://clinicaltrials.gov>
61. NLH. NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19. [cited 2020 18th May]; Available from: <https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19>
62. Gilead. Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19. [cited 2020 18th May]; Available from: <https://www.gilead.com/news-and-press/press->

[room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19](https://www.gilead.com/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19)

63. CDC. Avigan tablets 200 mg. [cited 2020 9th May]; Available from: https://www.cdc.gov/tw/File/Get/ht8jUiB_MI-aKnIwstwzvw
64. Shiraki K, Daikoku TJP, therapeutics. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. 2020: 107512.
65. Agency PaMD. Report on the Deliberation Results [cited 2020 09 May]; Available from: <https://www.pmda.go.jp/files/000210319.pdf>
66. Nguyen THT, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet A-M, et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. 2017; **11**(2): e0005389.
67. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020.
68. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020.
69. TAMIFLU® (oseltamivir phosphate). 2012 [cited 2020 9 May]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021087s062lbl.pdf
70. Davies BEJJoac. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. 2010; **65**(suppl_2): ii5-ii10.
71. He G, Massarella J, Ward PJCP. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. 1999; **37**(6): 471-84.
72. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochemical and biophysical research communications. 2004; **318**(3): 719-25.
73. Belubbi T, Shevade S, Dhawan V, Sridhar V, Majumdar A, Nunes R, et al. Lipid Architectonics for Superior Oral Bioavailability of Nelfinavir Mesylate: Comparative in vitro and in vivo Assessment. AAPS PharmSciTech. 2018; **19**(8): 3584-98.
74. Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, et al. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. The Pediatric infectious disease journal. 2003; **22**(1): 48-55.
75. CSH. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. [cited 2020 17th May]; Available from: <https://www.biorxiv.org/content/10.1101/2020.04.06.026476v1>
76. CSH. The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections. [cited 2020 17th May]; Available from: <https://www.biorxiv.org/content/10.1101/2020.04.24.060376v1>
77. Newsweek. NELFINAVIR AND CEPHARANTHINE SHOW SOME POTENTIAL AS COVID-19 TREATMENT IN LABORATORY TESTS. [cited 2020 17th May]; Available from: <https://www.newsweek.com/nelfinavir-cepharanthine-laboratory-tests-coronavirus-1498512>
78. Winzeler EA. Malaria research in the post-genomic era. Nature. 2008; **455**(7214): 751-6.
79. Parhizgar AR, Tahghighi A. Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review. Iranian journal of medical sciences. 2017; **42**(2): 115.
80. White N, Pukrittayakamee S, Hien T, Faiz M, Mokuolu O, Dondorp A. Malaria. Lancet [Internet]. 2014; 383 (9918): 723–35.
81. Frisk-Holmberg M, Bergqvist Y, Englund U. Chloroquine intoxication. British journal of clinical pharmacology. 1983; **15**(4): 502.
82. Lee S-J, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nature Reviews Nephrology. 2011; **7**(12): 718.
83. Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. International journal of antimicrobial agents. 2007; **30**(4): 297-308.
84. Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. Journal of clinical virology. 2001; **20**(3): 137-40.
85. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases. The Lancet infectious diseases. 2003; **3**(11): 722-7.
86. Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrobial agents and chemotherapy. 2009; **53**(8): 3416-21.
87. Tan YW, Yam WK, Sun J, Chu JJH. An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. Antiviral research. 2018; **149**: 143-9.
88. Yan Y, Zou Z, Sun Y, Li X, Xu K-F, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell research. 2013; **23**(2): 300-2.
89. Vigerust DJ, McCullers JA. Chloroquine is effective against influenza A virus in vitro but not in vivo.

Influenza and other respiratory viruses. 2007; **1**(5-6): 189-92.

90. Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. *The Lancet Infectious diseases*. 2011; **11**(9): 677-83.
91. Peymani P, Yeganeh B, Sabour S, Geramizadeh B, Fattahi MR, Keyvani H, et al. New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial). *Canadian journal of physiology and pharmacology*. 2016; **94**(6): 613-9.
92. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. *Biochemical and biophysical research communications*. 2004; **323**(1): 264-8.
93. Li R, Qiao S, Zhang G. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV. *Journal of Infection*. 2020; **80**(4): 469-96.
94. Feldman N. Possible treatment for COVID-19 enters clinical trial at Penn. 2020 [cited 2020 6th April]; Available from: <https://whyy.org/articles/possible-treatment-for-covid-19-enters-clinical-trial-at-penn/>
95. Simmons G, Bertram S, Glowacka I, Steffen I, Chaipan C, Agudelo J, et al. Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusion. *Virology*. 2011; **413**(2): 265-74.
96. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Bioscience trends*. 2020.
97. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. *The American journal of medicine*. 1983; **75**(1): 11-8.
98. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. *Clinical reviews in allergy & immunology*. 2012; **42**(2): 145-53.
99. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. *Lupus*. 1996; **5 Suppl 1**: S11-5.
100. Easterbrook M. Detection and prevention of maculopathy associated with antimalarial agents. *International ophthalmology clinics*. 1999; **39**(2): 49-57.
101. Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. *Autophagy*. 2018; **14**(8): 1435-55.
102. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. *The Lancet infectious diseases*. 2006; **6**(2): 67-9.
103. FDA. Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease [cited 2020 6th April]; Available from: <https://www.fda.gov/media/136534/download>
104. BENDER K. Results from a Controlled Trial of Hydroxychloroquine for COVID-19. 2020 [cited 2020 6th April]; Available from: <https://www.contagionlive.com/news/results-from-a-controlled-trial-of-hydroxychloroquine-for-covid19>
105. Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International journal of antimicrobial agents*. 2020: 105949.
106. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *MedRxiv*. 2020.
107. Canga AG, Prieto AMS, Liébana MJD, Martínez NF, Vega MS, Vieitez JJG. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. *The AAPS journal*. 2008; **10**(1): 42-6.
108. Götz V, Magar L, Dornfeld D, Giese S, Pohlmann A, Höper D, et al. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. *Scientific reports*. 2016; **6**(1): 1-15.
109. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β -mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. *Biochemical Journal*. 2012; **443**(3): 851-6.
110. Baraka O, Mahmoud B, Marschke C, Geary T, Homeida M, Williams J. Ivermectin distribution in the plasma and tissues of patients infected with *Onchocerca volvulus*. *European journal of clinical pharmacology*. 1996; **50**(5): 407-10.
111. Marty FM, Lowry CM, Rodriguez M, Milner DA, Pieciak WS, Sinha A, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. *Clinical Infectious Diseases*. 2005; **41**(1): e5-e8.
112. Zeng Z, Andrew N, Arison B, Luffer-Atlas D, Wang R. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. *Xenobiotica*. 1998; **28**(3): 313-21.
113. Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen®-based assay for high-throughput screening for specific inhibitors of nuclear import. *Journal of biomolecular screening*. 2011; **16**(2): 192-200.
114. Tay M, Fraser JE, Chan W, Moreland NJ, Rathore AP, Wang C, et al. Nuclear localization of dengue virus (DENV) 1–4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. *Antiviral research*. 2013; **99**(3): 301-6.
115. Wulan WN, Heydet D, Walker EJ, Gahan ME, Ghildyal R. Nucleocytoplasmic transport of nucleocapsid

proteins of enveloped RNA viruses. *Frontiers in microbiology*. 2015; **6**: 553.

116. Wurm T, Chen H, Hodgson T, Britton P, Brooks G, Hiscox JA. Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division. *Journal of virology*. 2001; **75**(19): 9345-56.

117. Hiscox JA, Wurm T, Wilson L, Britton P, Cavanagh D, Brooks G. The coronavirus infectious bronchitis virus nucleoprotein localizes to the nucleolus. *Journal of virology*. 2001; **75**(1): 506-12.

118. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral research*. 2020: 104787.